Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Lonza Bend Inc. is currently navigating 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct examiners and 2 distinct art units. This distribution shows a high level of diversification for the portfolio, as each pending matter is being handled by a different person in a different administrative unit.
PARK, HAEJIN S is the busiest examiner for the company, with 1 busiest examiner pending action. Since there are 2 pending office actions in total, PARK, HAEJIN S's workload represents half of the company's current prosecution activity. The remaining action is handled by the second of the 2 distinct examiners, ensuring that no single examiner or art unit dominates the portfolio's progress.
The fact that 2 pending office actions are located in 2 distinct art units suggests that the company's pharmaceutical interests are technically varied. This 1 to 1 ratio of actions to art units and examiners means the company is receiving diverse feedback from the patent office. Practitioners should prepare for different procedural styles given the involvement of 2 distinct examiners across 2 separate units, including the 1 busiest examiner pending action.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARK, HAEJIN S | 1 | 55.1% | +38.3% |
| KIM, DANIELLE A | 1 | 36.6% | +51.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18589995 | INHALABLE DRY POWDER FORMULATIONS COMPRISING ANGIOGENESIS INHIBITORS | PARK, HAEJIN S | 56d |
| 18247363 | ACETIC ACID AS PROCESSING AID IN SPRAY DRYING FOR BASIC DRUGS | KIM, DANIELLE A | 76d |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18589995 | INHALABLE DRY POWDER FORMULATIONS COMPRISING ANGIOGENESIS INHIBITORS | PARK, HAEJIN S | 1614 | §103DP | Final Rejection | 56d | Pending | Feb 28, 2024 |
| 18247363 | ACETIC ACID AS PROCESSING AID IN SPRAY DRYING FOR BASIC DRUGS | KIM, DANIELLE A | 1613 | §103 | Non-Final OA | 76d | Pending | Mar 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLonza Bend Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Haejin S Park has the most, with 1 of Lonza Bend Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
